Skip to main content

Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.

Publication ,  Journal Article
Lakhashe, SK; Wang, W; Siddappa, NB; Hemashettar, G; Polacino, P; Hu, S-L; Villinger, F; Else, JG; Novembre, FJ; Yoon, JK; Lee, SJ ...
Published in: PLoS One
2011

A safe, efficacious vaccine is required to stop the AIDS pandemic. Disappointing results from the STEP trial implied a need to include humoral anti-HIV-1 responses, a notion supported by RV144 trial data even though correlates of protection are unknown. We vaccinated rhesus macaques with recombinant simian immunodeficiency virus (SIV) Gag-Pol particles, HIV-1 Tat and trimeric clade C (HIV-C) gp160, which induced cross-neutralizing antibodies (nAbs) and robust cellular immune responses. After five low-dose mucosal challenges with a simian-human immunodeficiency virus (SHIV) that encoded a heterologous R5 HIV-C envelope (22.1% divergence from the gp160 immunogen), 94% of controls became viremic, whereas one third of vaccinees remained virus-free. Upon high-dose SHIV rechallenge, all controls became infected, whereas some vaccinees remained aviremic. Peak viremia was inversely correlated with both cellular immunity (p<0.001) and cross-nAb titers (p<0.001). These data simultaneously linked cellular as well as humoral immune responses with the degree of protection for the first time.

Duke Scholars

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2011

Volume

6

Issue

7

Start / End Page

e22010

Location

United States

Related Subject Headings

  • tat Gene Products, Human Immunodeficiency Virus
  • Viremia
  • Viral Vaccines
  • Vaccines, Synthetic
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Macaca mulatta
  • Infant
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lakhashe, S. K., Wang, W., Siddappa, N. B., Hemashettar, G., Polacino, P., Hu, S.-L., … Rasmussen, R. A. (2011). Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One, 6(7), e22010. https://doi.org/10.1371/journal.pone.0022010
Lakhashe, Samir K., Wendy Wang, Nagadenahalli B. Siddappa, Girish Hemashettar, Patricia Polacino, Shiu-Lok Hu, François Villinger, et al. “Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.PLoS One 6, no. 7 (2011): e22010. https://doi.org/10.1371/journal.pone.0022010.
Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu S-L, et al. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One. 2011;6(7):e22010.
Lakhashe, Samir K., et al. “Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.PLoS One, vol. 6, no. 7, 2011, p. e22010. Pubmed, doi:10.1371/journal.pone.0022010.
Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu S-L, Villinger F, Else JG, Novembre FJ, Yoon JK, Lee SJ, Montefiori DC, Ruprecht RM, Rasmussen RA. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One. 2011;6(7):e22010.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2011

Volume

6

Issue

7

Start / End Page

e22010

Location

United States

Related Subject Headings

  • tat Gene Products, Human Immunodeficiency Virus
  • Viremia
  • Viral Vaccines
  • Vaccines, Synthetic
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Macaca mulatta
  • Infant
  • Humans